Medically reviewed on August 22, 2018.
Applies to the following strengths: 2.5 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Migraine
Use only after a clear diagnosis of migraine has been established
Initial dose: 2.5 mg orally, once
-Provided there has been some response to first dose, a second dose may be administered at least 2 hours later if migraine returns or symptoms recur.
Maximum dose: 7.5 mg in a 24-hour period
-This drug should not be used to treat basilar or hemiplegic migraines because these patients are at a greater risk of stroke.
-The safety of treating an average of more than 4 migraine attacks in a 30 day period has not been established.
Use: For the acute treatment of migraine with or without aura.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
Mild to moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Use with caution as there is a greater potential for adverse events
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Take orally with water or other liquids
-A second dose should be taken no sooner than 2 hours after the first dose
-This drug should be used only where a clear diagnosis of migraine has been established; if a patient does not respond, the diagnosis of migraine should be reconsidered before treating subsequent attacks.
-This drug is not intended to treat cluster headaches, hemiplegic, or basilar migraines or for the prophylactic treatment of migraines.
-Patients with coronary artery disease (CAD) risk factors should have a cardiovascular evaluation performed prior to initiating therapy; for patients who satisfactorily complete a cardiovascular evaluation, consider administering first dose in a medically supervised setting and perform an ECG immediately following administration.
-Medication overuse headaches may present as migraine-like headaches or as a marked increase in migraine frequency; for patients using acute migraine medications (e.g. ergotamine, triptans, opioids) for 10 or more days per month consider withdrawal of the overused drugs and treatment of withdrawal symptoms.
-ECG monitoring should be considered in the interval following the first dose in patients with risk factors for coronary artery disease (CAD) who have satisfactorily completed a cardiovascular evaluation, consider periodic cardiovascular evaluation in intermittent long-term users with cardiovascular risk factors.
-Monitor blood pressure
-Monitor for serotonin syndrome if concomitant use of selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs) are necessary, particularly when starting therapy or with a new or increased dose of a serotonergic medication.
-Patients should be advised to talk with their doctor or pharmacist before taking any new medications or supplements.
-Patients should be aware of the risk of serious cardiovascular side effects and the importance of seeking medical advice promptly if they occur.
-Patients experiencing no relief from a first dose of this medication should be instructed not to take a second dose without first talking to their healthcare provider.
-Patients should be informed of the possibility of developing medication overuse headaches.
-This drug may impair judgment, thinking, or motor skills; have patient avoid driving or operating machinery until adverse effects are determined.
-Advise patient to speak to physician or health care professional if pregnant, intend to become pregnant, or are breastfeeding.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about frovatriptan
- Frovatriptan Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 41 Reviews
- Drug class: antimigraine agents
Other brands: Frova
- Frovatriptan Succinate (AHFS Monograph)
- Frovatriptan Succinate Tablets (FDA)
- Frovatriptan (Wolters Kluwer)